Vincerx Pharma (VINC) Proxy Filing summary

Executive summary

• Announced a proposed strategic merger between two biopharmaceutical companies to advance a promising anti-TROP2 ADC, OQY-3258, into global Phase 3 trials and expand a differentiated ADC pipeline.

• OQY-3258 has shown strong efficacy and a favorable safety profile in multiple breast cancer subtypes, including brain metastases, with ongoing Phase 1a/1b and Phase 3 trials.

• The merger is structured so Oqory equity holders will own about 95% of the combined entity, with a minimum $13.66 million equity value for existing Vincerx stockholders and a required $20 million concurrent private offering.

• Interim financing of $1.5 million is being provided to Vincerx, with closing of the merger subject to due diligence, financing, regulatory, and stockholder approvals.

• Forward-looking statements highlight the potential for innovation in next-generation ADCs and address significant unmet needs in oncology.

Voting matters and shareholder proposals

• Stockholder approval from both merging parties is required for the proposed merger to proceed.

• A definitive proxy statement will be sent to holders of common stock, and investors are urged to read all materials when available.

Board of directors and corporate governance

• Information about directors, nominees, and executive officers is available in prior proxy statements and SEC filings, with updates to be provided in future filings.

• Directors and officers of both companies may be considered participants in the proxy solicitation for the merger.